 Incidence neuropathy patients ovarian cancer cisplatin consecutive trials total patients ovarian cancer combination hexamethylmelamine cyclophosphamide methotrexate chemotherapeutic regimens cisplatin drug respect neurotoxicity patients eligible median follow-up survival months Neurotoxicity grade severity patients cisplatin-containing regimen non-cisplatin-containing regimen severity neurotoxicity cisplatin-treated patients Neurotoxicity-free survival cumulative doses cisplatin additional effect hexamethylmelamine incidence severity neurotoxicity patients years incidence cisplatin neuropathy Prognostic variables age International Federation Gynecology Obstetrics FIGO stage performance status others high-risk subgroups consistent factor neurotoxicity total dose cisplatin